• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Estimating survival in patients with lung cancer, brain metastases

Bioengineer by Bioengineer
November 17, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new article published online by JAMA Oncology updates a tool to estimate survival in patients with lung cancer and brain metastases.

Lung cancer is a leading cause of death in the United States and around the world. A frequent and serious consequence of the disease is metastasis to the brain. New therapies mean survival from lung cancer continues to improve and patients are at increased risk of developing later complications of the disease, such as brain metastases. Understanding prognosis for lung cancer is important, both for designing individualized care and future clinical trials.

In their article, Paul W. Sperduto, M.D., M.P.P., of Minneapolis Radiation Oncology and the University of Minnesota, Minneapolis, and coauthors update the original Diagnosis-Specific Graded Prognostic Assessment(DS-GPA) with new genetic and molecular data to create a new index called the Lung-moIGPA, which can be accessed electronically.

The updated Lung-moIGPA was designed by analyzing data from 2,186 patients in a multi-institution database from 2006 through 2014 with non-small cell lung cancer and newly diagnosed brain metastases. Two new prognostic factors were used in the new Lung-moIGPA: EGFR and ALK gene mutations. The authors reported overall median survival in the patient group was 12 months.

Study limitations include its design, which cannot establish causality.

"The updated Lung-moIGPA incorporating gene alteration data into the DS-GPA is a user-friendly tool that may facilitate clinical decision-making and appropriate stratification of future clinical trials," the study concludes.

###

(JAMA Oncol. Published online November 17, 2016. doi:10.1001/jamaoncol.2016.3834; available pre-embargo at the For The Media website.)

Editor's Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Contact

Caroline Marin
[email protected]
612-624-5680
@JAMA_current

http://www.jamamedia.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

3D-Printed Scaffolds Advance Glioblastoma Drug Screening

October 26, 2025

Evidence-Based Model for Public Health Nursing in Japan

October 25, 2025

Intrahepatic Cholangiocarcinoma: Key Updates from Guidelines

October 25, 2025

Investigating Rheum wittrockii Seed Surfaces in Kazakhstan

October 25, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1282 shares
    Share 512 Tweet 320
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    309 shares
    Share 124 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    193 shares
    Share 77 Tweet 48
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    133 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

3D-Printed Scaffolds Advance Glioblastoma Drug Screening

Evidence-Based Model for Public Health Nursing in Japan

Intrahepatic Cholangiocarcinoma: Key Updates from Guidelines

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.